Autopsy report · NCT03926637
Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis
Cause of deathOther
“Biogen will stop any further development of the MSPT. The data collected thus far in the MSPT Feasibility Study allow us to answer the primary study objectives that are associated with assessing the feasibility of the MSPT in a clinical care setting.”
Life of this trial
- Registered 2 months before it started.
- Ran for about 3 years 6 months before it stopped.
- 3,073 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Sponsor
- Biogen
- Sponsor type
- Industry
- Conditions
- Multiple Sclerosis
- Interventions
- Multiple Sclerosis Performance Test (MSPT)
- Participants
- 3,073
- Sites
- 33
- Countries
- Czechia, France, Italy, Switzerland, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.